While the SCLC-A-MKI67 cluster could be eliminated by initial treatment, the SCLC-A-CRIP2 cluster remained the major cancer cell type in the posttreatment samples, suggesting its potential role in drug resistance and relapse. This evidence concerns the gene CRIP2 and small cell lung carcinoma.